Loading clinical trials...
Loading clinical trials...
A Phase I/II, Multicenter, Open-Label, Nonrandomized Study to Evaluate the Tolerability and Safety of ASTX660 and the Efficacy at the Recommended Dose of ASTX660 in Patients With Relapsed or Refractory T-Cell Lymphoma
Conditions
Interventions
ASTX660
ASTX660
+1 more
Locations
1
Japan
Yamagata University Hospital
Yamagata, Japan
Start Date
July 14, 2020
Primary Completion Date
November 30, 2024
Completion Date
November 30, 2024
Last Updated
February 25, 2026
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions